Hepatitis C virus-specific cellular immune responses in sustained virological responders with viral persistence in peripheral blood mononuclear cells

Liver International

Volumn 34, Issue 6, 2014, Pages

  Roque Cuéllar, María C ^a   Sánchez, Berta ^a   García Lozano, José R ^a   Praena Fernández, Juan M ^a   Márquez Galán, José L ^b   Núñez Roldán, Antonio ^a   Aguilar Reina, José ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Flow cytometry; Occult HCV infection; Peripheral blood mononuclear cells; Real time PCR; Sustained virological responders; T cell response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA INTERFERON; INTERLEUKIN 4; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER; CD69 ANTIGEN; IFNG PROTEIN, HUMAN; IL4 PROTEIN, HUMAN; LECTIN; LEUKOCYTE ANTIGEN; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3 PROTEIN, HEPATITIS C VIRUS; NS4B PROTEIN, FLAVIVIRUS; PEPTIDE FRAGMENT; T LYMPHOCYTE ANTIGEN; VIRUS PROTEIN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SUBPOPULATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS SUBTYPE 1A; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; BLOOD; CASE CONTROL STUDY; DRUG EFFECTS; GENETICS; HEPACIVIRUS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; TIME; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-4; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS; CHINA; GENES, VIRAL; GENOTYPE;

EID: 84902550641     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12320     Document Type: Article

References (43)

1. World Health Organization (WHO) July 2012. http://www.who.int/mediacentre/factsheets/fs164/en/.
2. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-6.
3. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81: 1631-48.
4. Pham TN, Coffin CS, Michalak TI. Occult hepatitis C virus infection: what does it mean? Liver Int 2010; 30: 502-11.
5. Pham TN, MacParland SA, Mulrooney PM, et al. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004; 78: 5867-74.
6. MacParland SA, Pham TN, Guy CS, Michalak TI. Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology 2009; 49: 1431-41.
7. Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut 2012; 61: 1226-34.
8. Zhang X, Dou J, Germann MW. Characterization of the cellular immune response in hepatitis C virus infection. Med Res Rev 2009; 29: 843-66.
9. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-29.
10. Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet 2002; 359: 1478-83.
11. Castillo I, Rodríguez Íñigo E, Bartolomé J, et al. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut 2005; 54: 682-5.
12. Castillo I, Rodríguez-Íñigo E, López-Alcorocho JM, et al. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006; 43: 1277-83.
13. Pham TN, King D, Macparland SA, et al. Hepatitis C virus replicates in the same immune subsets in chronic hepatitis C and occult infection. Gastroenterology 2008; 134: 812-22.
14. Pham TN, Michalak TI. Occult persistence and lymphotropism of hepatitis C virus infection. World J Gastroenterol 2008; 14: 2789-93.
15. Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Diagnosis of occult hepatitis C without the need for a liver biopsy. J Med Virol 2010; 82: 1554-9.
16. Mohamad HI, El Bab HK, Kamal AM. Hepatitis C virus RNA in serum and peripheral blood mononuclear cells after successful interferon therapy. Hepatogastroenterology 2011; 58: 932-6.
17. Zaghloul H, El-Sherbiny W. Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. Immunol Invest 2010; 39: 284-91.
18. Roque-Cuéllar MC, Sánchez B, García-Lozano JR, et al. Expression of CD81, SR-BI and LDLR in lymphocytes and monocytes from patients with classic and occult hepatitis C virus infection. J Med Virol 2012; 84: 1727-36.
19. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
20. + Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 2005; 175: 3603-13.
21. Roque-Cuéllar MC, Sánchez B, García-Lozano JR, et al. Cellular immune responses and occult infection in seronegative heterosexual partners of chronic hepatitis C patients. J Viral Hepat 2011; 18: e541-9.
22. Aberle JH, Formann E, Steindl-Munda P, et al. Prospective study of viral clearance and CD4 (+) T-cell response in acute hepatitis C primary infection and reinfection. J Clin Virol 2006; 36: 24-31.
23. Sreenarasimhaiah J, Jaramillo A, Crippin J, et al. Concomitant augmentation of type 1 CD4 + and CD8 + T-cell responses during successful interferon-alfa and ribavirin treatment for chronic hepatitis C virus infection. Hum Immunol 2003; 64: 497-504.
24. Quiroga JA, Llorente S, Castillo I, et al. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection. J Med Virol 2006; 78: 1190-7.
25. Castillo I, Pardo M, Bartolomé J, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2003; 189: 7-14.
26. De Marco L, Gillio-Tos A, Fiano V, et al. Occult HCV infection: An unexpected finding in a population unselected for hepatic disease. PLoS ONE 2009; 4: e8182.
27. Castillo I, Bartolomé J, Quiroga JA, et al. Hepatitis C virus infection in the family setting of patients with occult hepatitis C. J Med Virol 2009; 81: 1198-203.
28. Quiroga JA, Llorente S, Castillo I, et al. Cellular immune response associated with occult hepatitis C virus infection of the liver. J Virol 2006; 80: 10972-9.
29. Kamal SM, Amin A, Madwar M, et al. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol 2004; 78: 12252-8.
30. Zeremski M, Shu MA, Brown Q, et al. Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat 2009; 16: 10-20.
31. Thurairajah PH, Hegazy DM, Chokshi S, et al. Hepatitis C virus (HCV)-specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis 2008; 198: 1749-55.
32. Freeman AJ, Ffrench RA, Post JJ, et al. Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use. J Infect Dis 2004; 190: 1093-7.
33. Kondo Y, Ueno Y, Kakazu E, et al. Lymphotropic HCV strain can infect human primary naïve CD4 + cells and infect their proliferation and IFN-γ secretion activity. J Gastroenterol 2011; 46: 232-41.
34. Sugden PB, Cameron B, Bull R, White PA, Lloyd AR. Occult infection with hepatitis C virus: friend or foe? Immunol Cell Biol 2012; 90: 763-73.
35. Pham TN, Mercer SE, Michalak TI. Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles. J Viral Hepat 2009; 16: 547-56.
36. Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Long-term virological follow up of patients with occult hepatitis C virus infection. Liver Int 2011; 31: 1519-24.
37. Stamataki Z. Hepatitis C infection of B lymphocytes: more tools to address pending questions. Expert Rev Anti Infect Ther 2010; 8: 977-80.
38. Marukian S, Jones CT, Andrus L, et al. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 2008; 48: 1843-50.
39. Welker MW, Zeuzem S. Occult hepatitis C: How convincing are the current data? Hepatology 2009; 49: 665-75.
40. Carreño V, Bartolomé J, Castillo I, Quiroga JA. New perspectives in occult hepatitis C virus infection. World J Gastroenterol 2012; 18: 2887-94.
41. Ducoulombier D, Roque-Afonso AM, Di Liberto G, et al. Frequent compartimentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 2004; 39: 817-25.
42. Durand T, Di Liberto G, Colman H, et al. Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes. Gut 2010; 59: 934-42.
43. Zignego AL, Gragnani L, Giannini C, Laffi G. The hepatitis C virus infection as a systemic disease. Intern Emerg Med 2012; 7: S201-8.